Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: A randomised controlled trial

Gut

Volumn 52, Issue 12, 2003, Pages 1768-1773

  Poon, R T P ^a,b   Yeung, C ^b   Liu, C L ^b   Lam, C M ^b   Yuen, W K ^b   Lo, C M ^b   Tang, A ^b   Fan, S T ^b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; SEDATIVE AGENT; SOMATOSTATIN; SOMATOSTATIN UCB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HEALTH CARE COST; HUMAN; HYPERAMYLASEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SPHINCTEROTOMY;

ACUTE DISEASE; AGED; AMYLASES; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DOUBLE-BLIND METHOD; FEMALE; HORMONES; HUMANS; HYPERAMYLASEMIA; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANCREATITIS; SOMATOSTATIN;

EID: 0344665557     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.12.1768     Document Type: Article

References (32)

1. Sherman S, Hawes RH, Rathgaber SW, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low-and high-osmolality contrast agent. Gastrointest Endosc 1994;40:422-7.
2. Gottlieb K, Sherman S, Pezzi J, et al. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol 1996;91:1553-7.
3. Dumot JA, Canwell DL, O'Connor JB, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: a randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998;93:61-5.
4. Budzynska A, Marek T, Nowak A, et al. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis. Endoscopy 2001;33:766-72.
5. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. Gastrointest Endosc 2002;56:202-8.
6. Poon RT, Yeung C, Lo CM, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999;49:593-8.
7. Bordas JM, Toledo-Pimentel V, Llach J, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998;47:230-4.
8. Binmoeller KF, Harris AG, Dumas R, et al. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992;33:1129-33.
9. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001;15:965-72.
10. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy-Italian Group. N Engl J Med 1996;335:919-23.
11. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000;51:1-7.
12. Testoni PA, Masci E, Bagnolo F, et al. Endoscopic papillo-sphincterotomy: prevention of pancreatic reaction by somatostatin. Ital J Gastraenterol 1988;20:70-3.
13. Guelrud M, Mendoza S, Viera L, et al. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1991;37:44-7.
14. Persson B, Slezak P, Efendic S, et al. Can somatostatin prevent infection pancreatitis after ERCP? Hepatogastroenterology 1992;39:259-61.
15. Freeman ML, Nelson DB, Sherman S, et al. Same day discharge after endoscopic biliary sphincterotomy: observations from a prospective multicenter complication study. The Multicenter Endoscopic Sphincterotomy (MESH) Study Group. Gastrointest Endosc 1999;49:580-6.
16. Ho KY, Montes H, Sossenheimer MJ, et al. Features that may predict hospital admission following outpatient therapeutic ERCP. Gastrointest Endosc 1999;49:587-92.
17. Cotton PB, Lehman G, Vennes J, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-93.
18. Sherman S, Lehman GA. ERCP-and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991;6:350-67.
19. Sherman S, Ruffolo TA, Hawes RH, et al. Complications of endoscopic sphincterotomy: a prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991;101:1068-75.
20. Johnson GK, Geenen JE, Bedford RA, et al. A comparison of nonionic versus ionic contrast media: results of a prospective multicenter study. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1995;42:312-16.
21. Vandervoort J, Soetikno RM, Than TC, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002;56:652-6.
22. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18.
23. Poon RT, Fan ST. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. JOP 2003;4:33-40.
24. Binmoeller KF, Dumas R, Harris AG, et al. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992;37:773-7.
25. Ahrendt SA, McGuire GE, Lillemore KD, et al. Somatostatin inhibits sphincter of Oddi motility. Gastroenterology 1990;98:A242.
26. Devière J, Le Moine O, Van Laethem JL, et al. Interleukin-10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001;120:498-505.
27. Dumot JA, Conwell DL, Zuccaro G Jr, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001;96:2098-102.
28. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001;54:425-34.
29. Messman H, Vogt W, Holstege A, et al. Post-ERCP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997;40:80-5.
30. Karalis K, Mastorakos G, Chrousos GP, et al. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994;93:2000-6.
31. Yuan Y, Gong Z, Lou K, et al. Effects and mechanisms of somatostatin analogs on apoptosis of pancreatic acinar cells in acute pancreatitis in mice. J Gastroenterol Hepatol 2001;16:683-8.
32. Andriulli A, Leandro G, Clemente R, et al. Meta-analysis of somatostatin, octreotide and gabexate mesilate in the therapy of acute pancreatitis. Aliment Pharmacol Ther 1998;12:237-45.